Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...

It was FDA approved based on a clinical trial that showed it, overall, delayed the onset of insulin dependence from two years ...

Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

The MongoDB chart shows the stock pulling back in the past ... buoyed by strong sales of weight-loss drug Zepbound and diabetes treatment Mounjaro Analysts expect Lilly earnings to grow by 96% this ...

Before the rise of diabetes medications from companies like Eli Lilly & Co. (NYSE: LLY ... investors may still be able to get a premium from Hess shares. The Wynn Resorts chart shows a stock that's ...

The second reason I highlight is Eli Lilly's Mounjaro, which is actively increasing its share in the type 2 diabetes treatment ... However, if you look at the chart below, this implies a ...